- Home
- CKPT
as 05-09-2025 4:00pm EST
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Upcoming Earnings Alert:
Get ready for potential market movements as Checkpoint Therapeutics Inc. CKPT prepares to release earnings report on 16 May 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 335.9M | IPO Year: | 2017 |
| Target Price: | $4.33 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.47 - $4.50 | Next Earning Date: | 05-16-2025 |
| Revenue: | $41,000 | Revenue Growth: | -60.19% |
| Revenue Growth (this year): | 102182.93% | Revenue Growth (next year): | 351.71% |
Stock Insider Trading Activity of Checkpoint Therapeutics Inc. (CKPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Oliviero James F III | CKPT | CEO, President and Director | Apr 2 '25 | Sell | $4.04 | 15,090 | $60,963.60 | 3,759,929 | |
| GRAY WILLIAM GARRETT | CKPT | Chief Financial Officer | Apr 1 '25 | Sell | $4.05 | 12,322 | $49,904.10 | 1,446,322 |
Latest Checkpoint Therapeutics Inc. News
CKPT Breaking Stock News: Dive into CKPT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
High Growth Tech Stocks in the US for April 2025
Simply Wall St.
a month ago
3 Growth Companies Insiders Are Betting On
Simply Wall St.
a month ago
Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023)
GlobeNewswire
a month ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Simply Wall St.
2 months ago
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shift From Loss To Profit
MT Newswires
2 months ago
HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target
MT Newswires
2 months ago
Sector Update: Health Care Stocks Decline Late Afternoon
MT Newswires
2 months ago
Sector Update: Health Care Stocks Decline Monday Afternoon
Compare CKPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CKPT Checkpoint Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.